Improving Outcomes in Non-Small Cell Lung Cancer
Amivantamab, Chemotherapy Improves PFS in EGFR NSCLC with Exon 20 Mutations
December 1, 2023The addition of amivantamab to chemotherapy improved outcomes compared to chemotherapy alone as a first-line treatment for patients with EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC)...
Datopotamab Deruxtecan Safe, Effective for Patients with Heavily Pretreated NSCLC
October 20, 2023The antibody-drug conjugate datopotamab deruxtecan demonstrated encouraging antitumor activity in patients with heavily pretreated non-small cell lung cancer (NSCLC)...
Responding Patients with NSCLC Can Safely Discontinue Immunotherapy After 2 Years
August 7, 2023Overall survival (OS) outcomes did not significantly differ between patients with advanced non-small cell lung cancer (NSCLC) who received immunotherapy indefinitely or for a fixed duration...
Prior Treatments, Genomic Factors Associated with Sotorasib Response, Toxicity in Real-World Setting
August 7, 2023A retrospective study published in JCO Precision Oncology identified factors associated with clinical response and toxicity in patients taking sotorasib for advanced KRASG12C-mutant non-small cell lung cancer (NSCLC)...
Future of Resectable NSCLC Lies in Optimal Treatment Duration, Reliable Surrogate Endpoints
August 7, 2023The future of adjuvant and neoadjuvant treatments for early-stage resectable non-small cell lung cancer will involve identifying biomarkers to determine which patients can benefit from perioperative immunotherapy and targeted therapy...